logo
"AMCA open for private sector": Defence Secy Rajesh Kumar Singh emphasises need for private players in fighter jet production

"AMCA open for private sector": Defence Secy Rajesh Kumar Singh emphasises need for private players in fighter jet production

India Gazette12 hours ago

New Delhi [India], June 20 (ANI): Emphasising the importance of private sector involvement in the defence aviation industry, Defence Secretary Rajesh Kumar Singh said on Friday that the production of India's fifth-generation fighter jet, the Advanced Medium Combat Aircraft (AMCA), will be open to private companies.
In an exclusive interview with ANI, Defence Secretary Rajesh Kumar Singh underscored the need for at least two aircraft manufacturers in India. He noted that the presence of private sector players would foster healthy competition, ultimately benefiting the country's public sector aerospace company, Hindustan Aeronautics Limited (HAL).
'We've not reached a stage where I can talk about anything specific being done. What I can talk about is that our fifth-generation fighter, which will be the AMCA...We've kept it open for the public and private sectors for the first time. The intent is that we need to have at least two aircraft manufacturers in the country, if not more. And once that gets some traction, we will hopefully move towards self-reliance in this critical area. For the AMCA, the timeline is about eight years,' Singh said.
Defence Minister Rajnath Singh had last month approved the Advanced Medium Combat Aircraft (AMCA) Programme Execution Model.
The Execution Model approach provides equal opportunities to both the private and public sectors on a competitive basis. They can bid either independently, as a joint venture, or as a consortium. The entity or bidder should be an Indian company that is compliant with the laws and regulations of the country.
The Defence Secretary said HAL will gain from healthy competition.
'There was a committee headed by me, which essentially sort of gave the report that we need to open it up for the entire manufacturing ecosystem of the country. Whoever wants to come in should come in and... HAL will also gain from healthy competition of this type,' he said.
Answering a query, he said HAL has the first-mover advantage and is the only military aircraft maker in the country, and there is a need to bring some competition.
'I would say to any premature criticism of HAL. HAL has its own constraints. I mean, the LCA production line has not stabilised, largely because of the delays in engine supplies from the US. But the fact is that they also have their order books full. I think that they already have six years of orders with them. They have their hands full as well. And therefore, I mean, you can't explicitly bar anybody from competing, particularly in the public sector. But you would like to create a level-playing field where others can also bid. They have the first-mover advantage. They are the only military aircraft maker in the country. So they will always have that advantage. But the intent is to bring in some competition, because monopolies are never good. For even a public sector monopoly,' Singh said.
The Defence Secretary stated that India's reliance on Russian defence equipment has declined compared to the past. He also noted that the country now imports defence equipment from a broader range of nations, including Israel, France, and the United States.
He pointed out that ongoing geopolitical tensions and global conflicts have impacted the timely delivery of defence equipment.
'Russians are one of our leading suppliers. I think the percentage would have come down...maybe 40 per cent or so, from about 65-70 per cent earlier. I mean, it's not just the Ukraine conflict, which, of course, it has affected some supplies from Russia, the prime example being the S-400s, which are delayed, but where we now have a firm schedule; they'll come next year by April, and one by April, one battery by the end of next year,' Singh said.
'Others - I mean, to be very frank, some of our contracts with Israel also got held up because of their issues, the conflict that they have. So yeah, it's probably inevitable. But the fact is that Israel, Russia, and France - these are ours, and increasingly the US also - they are some of our primary sorts of weapon suppliers now. And to some extent, all of them have been affected by the supply chain disruptions that came after COVID and thereafter by the geopolitical conflicts,' Singh said.
On whether India is eyeing American or Russian fifth-generation fighter jets, the Defence Secretary said that the discussions with the countries are not in the formal stage yet. 'I mean, whatever has been discussed has been informal. We don't really have any formal consultations going on on these. Our intent, of course, will have to be to acquire critical technologies through selective foreign purchases,' he added. (ANI)

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Amit Shah a disgrace to the post once held by Sardar Patel: Jairam Ramesh
Amit Shah a disgrace to the post once held by Sardar Patel: Jairam Ramesh

Business Standard

time21 minutes ago

  • Business Standard

Amit Shah a disgrace to the post once held by Sardar Patel: Jairam Ramesh

Congress General Secretary Jairam Ramesh on Friday launched a direct attack on Union Home Minister Amit Shah, accusing him of failing to "bring the terrorists who carried out the brutal terror attacks in Pahalgam to justice," and restoring peace in Manipur. "Amit Shah is a disgrace to the position once held by the indomitable Sardar," claimed Ramesh. "The Union Home Minister has failed singularly in bringing the terrorists who carried out the brutal terror attacks in Pahalgam to justice. These terrorists had reportedly also been involved in terror attacks at Poonch (Dec 2023) and at Gagangir and Gulmarg (Oct 2024)," his post said. "The Union Home Minister has failed miserably to restore even a semblance of peace and normalcy in Manipur. All that he has accomplished is to provide guaranteed employment to his son. Now the Union Home Minister makes the most ridiculous of statements. Millions of Indians each speak more Indian languages - in addition to English - than him. He is a disgrace to the position once held by the indomitable Sardar," said the post from Ramesh. Ramesh called the visit a "publicity-driven exercise" that fails to address the ground realities of the state. "The advertisement-loving Prime Minister is once again on a tour of matter how many fake announcements the Prime Minister makes, no matter how many ribbons he cuts for free advertising, the truth is that the double engine government in Bihar has completely failed to meet the expectations of the common people," his post read. "In Bihar, oppression against the deprived classes is at its peak, the law and order situation is extremely bad, criminals have become unbridled and the common citizens are helpless. Every day there are reports of murder, robbery and violence against youth do not have any employment in the state and they are forced to migrate from Bihar," he said. "During this visit, the Prime Minister will also express his electoral concern about the pollution of Mother Ganga .But the truth is that in the last 11 years, 'Ganga cleansing' has become just an election slogan, which is suddenly remembered before every election. Not only in Bihar, Mother Ganga has become more polluted than before in the entire country. Most of the schemes launched in the name of Ganga cleanliness campaign have proved to be a black hole of corruption-After the foundation stone laying, inauguration and heavy publicity, neither any work is visible nor any concrete National Green Tribunal (NGT) itself is exposing the terrible condition of Ganga pollution in Patna and Bihar," added Ramesh.

Four Indian pharma stocks that may be hit by US pharma tariff threat
Four Indian pharma stocks that may be hit by US pharma tariff threat

Mint

time30 minutes ago

  • Mint

Four Indian pharma stocks that may be hit by US pharma tariff threat

Indian pharma stocks took a beating on Tuesday, 17 June, after US President Donald Trump said tariffs on pharmaceutical imports are coming 'very soon." His comments sent shockwaves across the market, dragging the Nifty Pharma index down by over 2% intraday. It was the worst-performing sector of the day. This isn't the first time Trump has hinted at such a move. He had dropped clues back in April, but this latest announcement has added urgency and concern. The Indian pharma industry, which relies heavily on exports to the US for generics and speciality drugs, is now facing concerns over potential revenue disruptions. Any disruption in trade or pricing could have a direct impact on revenues and margins. In this article, we take a look at five Indian pharmaceutical companies that could be the most affected by the proposed US tariffs. #1 Granules India Granules India has a presence across the pharmaceutical manufacturing value chain, including active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediaries (PFIs) and finished dosages (FDs). It produces and supplies paracetamol, metformin, guaifenesin, and methocarbamol APIs. It has over 10 manufacturing facilities, approximately eight of which are located in India and two in the US. The company sells its products in global markets, including the United States of America, Canada, Latin America, Europe, Asia Pacific, and India. As per the FY24 annual report, 66% of Granules India's total revenue came from North America. This dependence has only deepened in recent quarters with the US market contributing 79% of revenue in the March 2025 quarter, according to the latest investor presentation. Data Source: Earnings Presentation FY25 and Q4 FY25 Given this significant exposure, any tariff-related cost increases could affect both the company's topline and margins. On 17 June 2025, executive director Priyanka Chigurupati said that the company is currently in the final stages of completing remediation work at its Gagillapur facility. It expects this process to wrap up in the next few months, after which a USFDA re-inspection is anticipated. Once this hurdle is cleared, Granules is aiming to launch 11 pending products in the US market, which were temporarily held back during the compliance phase. Production had been scaled down to prioritise remediation, but the company is now preparing to ramp up volumes again as operations stabilise. It's also working on its first major oncology product launch in the US, expected around FY28. To support its future growth strategy, the company is prepping its Genome Valley facility to meet upcoming USFDA and European audits. #2 Gland Pharma Gland Pharma has become a leader in generic injectables. Its presence spans 60 countries, including the US, Europe, Canada, and Australia. The company's business model primarily involves business-to-business, which contributes 98% of its revenue. It provides contract development, dossier compilation, and technology transfer services. The balance comes from business to consumer. Geographically, the company has a strong presence in the US, which contributes 54% of its revenue. Its revenue in the region has grown from ₹2,585 crore in FY22 to ₹3,037 crore in FY24. This makes the company vulnerable to tariffs. Recently, Gland Pharma received approval from the US Food and Drug Administration (US FDA) for Angiotensin II Acetate Injection. Since the company is the first to submit for exclusivity, it qualifies for 180 days of exclusivity for the generic drug. #3 Aurobindo Pharma Aurobindo Pharma has built a strong presence across more than 150 countries, manufacturing generic formulations, APIs, and injectables. It's the largest generic drug company in the US and ranks among the top 10 generic players in eight European countries. That's where the concern comes in. According to its FY24 annual report, half (48%) of Aurobindo's revenue comes from the US. Data Source: Aurobindo Pharma Annual Report 2023-24 As per the company's investor presentation in March 2025, it holds the top spot in the US in terms of oral solids prescription volume, commanding a 10.5% market share in the September 2024 quarter. So, when talk of new US tariffs on pharma imports hits the headlines, Aurobindo's heavy exposure naturally makes the stock vulnerable to a fall. On 16 June 2025, the company announced the incorporation of a new wholly owned subsidiary, Cresedemo Pharma LLC, in the US. This move aims to further strengthen its US pharma business. While the new entity signals Aurobindo's long-term commitment to the US market, the proposed tariffs could present near-term headwinds for the company. Looking ahead, Aurobindo is placing a big bet on the future of biosimilars. With 14 promising products currently in the pipeline, the company is eyeing a massive US$ 50 bilion+ market opportunity. If things go as planned, this could open up an exciting new growth path and offer some much-needed cushion against any potential policy shocks like the proposed US tariffs. Also Read: India seeks financial details of pharmaceutical marketing practices, industry caught in a bind #4 Dr Reddy's Laboratories Dr Reddy's Lab is one of India's largest pharmaceutical firms in the country. The company manufactures a wide range of pharmaceuticals with expertise spanning several therapeutic areas. Through its step-down subsidiary Aurigene Pharmaceutical Services Ltd (APSL), it's making strong strides in the CDMO space. APSL acts as a comprehensive Contract Research, Development, and Manufacturing Organization (CRO/CDMO), offering end-to-end solutions to global pharmaceutical and speciality companies. It has cGMP manufacturing facilities in the UK, Mexico, USA, and India, enabling it to serve a global clientele. Despite this global footprint, a large chunk of Dr Reddy's revenue still comes from the US. Also, the latest investor presentation of Q4FY25, shows 42% of the total revenue from the US market. This heavy dependence on the US leaves the company exposed to the potential impact of new tariffs. In response to increasing tariff speculation, the company has indicated a desire to consider local manufacturing in the US, through acquisitions. This will not only help reduce the risk of import duties but will also deepen its foot in one of its most important markets. Meanwhile, Dr Reddy focuses on maintaining its growth. The company plans to launch 15-20 new products in the US every year. Also Read: Dr. Reddy's focused on securing supply chains amid US tariff uncertainty Conclusion While the possibility of imports has rattled the sector, it's important to take a balanced view before making investment decisions. There's no denying that companies with high revenue exposure to the US, like Aurobindo Pharma, Granules India, and Dr Reddy's could face near-term challenges if such tariffs are implemented. Margins may come under pressure and growth plans might require changes. However, the long-term fundamentals of India's pharmaceutical industry remain strong. The government is actively supporting the sector through key initiatives such as the Production Linked Incentive (PLI) Scheme for Pharmaceuticals, Promotion of Bulk Drug Parks, Pharmaceutical Technology Upgradation Assistance Scheme (PTUAS), and the Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP), which aims to make quality medicines accessible at affordable prices. Moreover, according to a recent EY-FICCI report, the Indian pharmaceutical market is poised to reach a value of around $130 billion by 2030, signalling strong growth potential. It's important to conduct thorough research on financials and corporate governance before making investment decisions, ensuring they align with your financial goals and risk tolerance. Happy Investing. Disclaimer: This article is for information purposes only. It is not a stock recommendation and should not be treated as such. This article is syndicated from

Operation Sindhu: Big relief for India as 290 students return from Iran, land in Delhi
Operation Sindhu: Big relief for India as 290 students return from Iran, land in Delhi

India.com

time31 minutes ago

  • India.com

Operation Sindhu: Big relief for India as 290 students return from Iran, land in Delhi

Operation Sindhu: Big relief for India as 290 students return from Iran, land in Delhi Iran-Israel war: A flight from Mashhad, Iran, carrying 290 Indian students, mostly from Jammu and Kashmir, landed at the Delhi Airport late Friday. With this, so far 517 Indian nationals from Iran have returned home under Operation Sindhu. The Indian government has launched Operation Sindhu to evacuate its nationals from the Middle Eastern country as hostilities escalate between Israel and Iran. Two more flights are scheduled to arrive later in the night, including one from Ashgabat, Turkmenistan, around 3 am, bringing home around 1,000 Indian nationals. 'Heartfelt thanks to the Government of India, Ministry of External Affairs, and all concerned authorities for their timely intervention and support. A great relief for families who had been anxiously awaiting their return,' the Jammu and Kashmir Students Association said in a statement. In a special gesture, Iran opened its airspace to facilitate India's evacuation efforts. Students were earlier moved to Mashhad from Tehran, and the flights operated by an Iranian airline were coordinated by Indian authorities. The evacuation follows days of aerial bombardments and retaliatory strikes between Iran and Israel. On Thursday, 110 Indian students were evacuated via Armenia and Doha before reaching Delhi. The Ministry of External Affairs launched Operation Sindhu last week. (With agency inputs)

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store